ZEISS is now offering cataract surgeons more possibilities through the introduction of the CT LUCIA hydrophobic monofocal intraocular lens

Doctors benefit from simple workflows, and patients from the excellent¹ visual outcomes

At this year's summer meeting of the European Society of Cataract and Refractive Surgery (ESCRS) in London medical technology provider ZEISS is presenting a new aspheric monofocal IOL. The C-loop design of the CT LUCIA® has been implemented using glistening-free² hydrophobic material. An innovative preloaded injector enables outstanding ease of use. With the introduction of this new product, ZEISS now offers the most comprehensive IOL portfolio in the market – for all applications and requirements.

JENA/Germany, LONDON/UK, 13/09/2014.

ZEISS is strengthening its offering of monofocal IOLs for cataract surgeons with the addition of the new CT LUCIA IOL featuring a C-loop design. It is made of glistening-free² material and incorporates ZEISS aspheric aberration correcting optics. It is available with a fully preloaded injector system that guarantees excellent ease of use and smooth unfolding of the IOL. Due to the optical design of the lens, patients benefit from enhanced visual outcomes¹. The lens offers cataract surgeons streamlined workflows before and during the surgery.

"With the most comprehensive IOL portfolio on the market, we can now address the needs of all customer segments,", says Dr. Ludwin Monz, CEO of Carl Zeiss Meditec AG. "The new lens stands for ZEISS standards in optics and quality."

ZEISS already offers a wide variety of hydrophilic IOLs with an extensive diopter range which are suitable for Micro Incision Cataract Surgery (MICS). As a solutions provider, ZEISS is additionally presenting a complete workflow for cataract surgery to its customers. Each individual component meets the highest requirements. In combination, they optimize the workflow – starting from gold standard biometry to visualization solutions for IOL implantation.

The new CT LUCIA is going to be on display at the ZEISS booth during the ESCRS.

The C-loop design of the new IOL CT LUCIA has been implemented using glisteing-free hydrophobic biomaterial.

The C-loop design of the new IOL CT LUCIA has been implemented using glisteing-free hydrophobic biomaterial.

Image Download (JPG File · 1 MB)

With ints innovative preloaded injector the CT LUCIA form ZEISS enables outstanding ease of use.

With ints innovative preloaded injector the CT LUCIA form ZEISS enables outstanding ease of use.

Image Download (JPG File · 1 MB)

Press contact:
Poppy Smith, Marketing Executive, Carl Zeiss Meditec UK
Phone: +49 1223 4014701, Email: poppy .smith @zeiss .com


For investors:
Sebastian Frericks, Investor Relations, Carl Zeiss Meditec AG
Phone: +49 3641 220-116, Email: investors .meditec @zeiss .com

 

 

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualisation solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

  • 1 Maedel S et al. Effect of heparin coating of a foldable intraocular lens on inflammation and capsular bag performance after cataract surgery. JCRS 2013
  • 2 Rosca, G. “High Precision Injection with a New Heparin Coated Hydrophobic One Piece IOL”, presented at ASCRS, Chicago, 2012.
We use cookies on this site. Cookies are small text files that are stored on your computer by websites. Cookies are widely used and help to optimize the pages that you view. By using this site, you agree to their use. more